// App-Quantinova.ai

P1048 : MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR

Researchers

Presenter

  • John Mascarenhas

Principal Investigators

  • Claire N. Harrison

  • Jean-Jacques Kiladjian

  • Rami S. Komrokji

  • Steffen Koschmieder

  • Alessandro M. Vannucchi

  • Tymara Berry

  • Denise Redding

  • Laurie Sherman

  • Souria Dougherty

  • Lixian Peng

  • Libo Sun

  • Fei Huang

  • Ying Wan

  • Faye M. Feller

  • Aleksandra Rizo

  • Srdan Verstovsek

Medical Centers

  • RWTH Aachen University, Aachen, Germany

  • Geron Corporation,Parsippany, NJ,Stati Uniti

  • Hôpital Saint-Louis; Université de Paris; Inserm,Paris,France

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • The Tisch Cancer Institute, Icahn Sc

  • Guy's and St Thomas' Hospital,London,Royaume-uni

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Geron Corporation,Parsippany, NJ,Vereinigte Staaten

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Moffitt Cancer Center,Tampa, FL,Stati Uniti

  • RWTH Aachen University, Aachen, Germany

  • Guys and St ThomasHospital, London, UK

  • CRIMM, AOU Careggi, University of Florence, Florence, Italy

  • Guy's and St Thomas' Hospital,London,Reino Unido

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • H Lee Moffitt Cancer Center,Tampa, FL,Vereinigte Staaten

  • CRIMM, AOU Careggi, University of Florence, Florence, Italy

  • Hôpital Saint-Louis; Université de Paris; Inserm,Paris,France

  • Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai,New York,Vereinigte Staaten

  • Geron Corporation,P

  • Guy's and St Thomas' Hospital,London,Vereinigtes Königreich

  • CRIMM, AOU Careggi, University of Florence, Florence, Italy

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Guy's and St Thomas' Hospital,London,Reino Unido

  • Geron Corporation,Parsippany, NJ,Vereinigte Staaten

  • RWTH Aachen University,Aachen,Германия

  • RWTH Aachen University, Aachen, Germany

  • H Lee Moffitt Cancer Center,Tampa, FL,Vereinigte Staaten

  • Hôpital Saint-Louis; Université de Paris; Inserm,Paris,France

  • Geron Corporation,Parsippany, NJ,Stati Uniti

  • Geron Corporation,Parsippany, NJ,Vereinigte Staaten

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • AOU Careggi, University of Florence,

  • RWTH Aachen University, Aachen, Germany

  • RWTH Aachen University,Aachen,Tyskland

  • CRIMM, AOU Careggi, University of Florence, Florence, Italy

  • The University of Tokyo

  • H Lee Moffitt Cancer Center,Tampa, FL,Vereinigte Staaten

  • Hopital Saint-Louis, AP-HP, Universite Paris , Paris, France

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • Mofitt Cancer Center,Tampa, FL,Estados Unidos

  • RWTH Aachen University,Aachen,Tyskland

  • Moffitt Cancer Center,Tampa, FL,Stati Uniti

  • The University of Texas, MD Anderson Cancer Center,Houston, TX,Verenigde Staten

  • Guy's and St Thomas' Hospital,London,Vereinigtes Königreich

  • CRIMM, AOU Careggi, University of Florence, Florence, Italy

  • Geron Corporation,Parsippany, NJ,Stati Uniti

  • RWTH Aachen University,Aachen,Tyskland

  • Hôpital Saint-Louis; Université de Paris; Inserm,Paris,France

  • CRIMM, AOU Careggi, University of Florence, Florence, Italy

  • H. Lee Moffitt Cancer Center

  • Hôpital Saint-Louis, Université Pa

  • RWTH Aachen University, Aachen, Germany

Locations

  • United States

  • United Kingdom

  • France

  • Germany

  • Italy

  • Turkey

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelofibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxyurea

  • Thalidomide

  • Imetelstat

  • Interferon

  • Danazol

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

  • Open Label

  • Multinational

  • Multicenteric

Phase

  • III

Study Id's

  • NCT04576156

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved